Research Library Membership
Executive research for leaders deciding what to fund, authorize, restrict, or examine next.
Our planned annual license is $7,500 for two named readers within the same company. Enrollment is not open. Read the public research while we prepare the member collection and verify delivery.
Public research
Explore our analysis before deciding whether the deeper research fits your work.
Start with
- Published articles and executive perspectives
- The current playbook's audio overview
- Clearly labeled illustrative samples
Annual Research License
A shared research collection for two named colleagues examining executive decisions.
Planned scope
- Full flagship playbooks
- Companion executive white papers
- Weekly brief and quarterly outlook recordings with written materials
- A reviewed archive of eligible prior research
Existing access
This planned offer does not replace an existing purchase or agreement.
Your current arrangement
- Existing rights remain governed by the terms already agreed
- Use your current sign-in for member access
- Contact us if you need help finding purchased material
This page describes an offer in preparation, not an open enrollment or a promise of immediate access. No payment is requested here.
What we are preparing
| Research | Planned role | Availability |
|---|---|---|
| Flagship playbooks and companion white papers | Connected analysis of one executive decision, with role-specific perspectives | Member editions and release schedule in preparation |
| Research reviews and briefings | Help readers examine new evidence and revisit earlier decisions | Weekly brief; four quarterly outlook recordings with written materials planned |
| Prior research archive | Eligible earlier work, labeled by date and edition | Subject to inventory, quality, access-rights, and delivery checks |
Questions
Start with the decision you need to examine. The public articles and samples can help you assess whether our approach is useful.
Who does the annual license cover?
The planned $7,500 annual license covers two named readers within the same company, each with a separate login. A reader may be replaced when staffing changes, with no more than two active readers at a time. It is not a whole-company or whole-board redistribution license. Renewal will be manual, not automatic.
Will full playbooks and white papers be included?
Yes, those formats are central to the planned member collection. Public articles will explain selected questions and findings; the full member editions will provide the connected research. We will identify the available titles before enrollment opens.
How often will new research arrive?
Our editorial baseline is one monthly flagship and six role white papers, a weekly research brief, and four asynchronous quarterly outlook recordings with written materials each year. We are verifying the capacity and delivery needed to support that baseline before enrollment. The weekly brief replaces a separate monthly newsletter; extra publications are bonuses. Enrollment is not open.
Is the entire historical archive ready?
No. Prior work must be inventoried and reviewed for source quality, edition status, access rights, and usable delivery before it is listed as part of the member collection. We are not promising a complete archive today.
Does membership include consulting or residency labs?
The planned license is for shared research, not custom research for each client, consulting, residency labs, or travel-based delivery. Any separate service would require its own agreed scope.
Does this change my existing purchase or membership?
No. Existing purchases and agreements retain their agreed rights. Use member sign in or contact us for help with your current access.
Examine the work before deciding.
Listen to the Agent Ready Data overview, read our public research, or ask about the planned annual license. Enrollment is not open yet.
The work is executive decision support. It is not legal advice, a compliance certification, or a promise of financial return or liability reduction. See the privacy policy.